On Tuesday, May 21, 2019, Boston Healthcare Associates hosts a national and international webinar on policies and utilization for next generation sequencing. It's at 11 eastern, 8 pacific, 4 pm UK, 5 pm Europe.
The first part of the webinar is led by myself - talking about the CMS NCD for next-generation sequencing. Boston Healthcare Associates presents new data on US/European NGS utilization and coming trends.
Register here before Tuesday. See the Boston Healthcare Associates homepage here.
Even though next-generation sequencing (NGS) cancer testing has moved from a rarity to a common feature of clinical practice in recent years, reimbursement policies for NGS testing still vary widely among private and public insurers across different countries
In the United States, both large commercial labs and large health systems offer NGS tumor testing, and it is anticipated that this landscape will change the availability of a US Food and Drug Administration (FDA)-approved NGS tumor panel. Meanwhile, healthcare systems in Europe are taking what is, in many ways, a very different approach to reimbursement of clinical sequencing with NGS. In France, for example, a network of regional laboratories will be reimbursed to provide molecular testing services. Similarly, genomic laboratory hubs will provide access to whole genome sequencing in the UK beginning in 2019.
In this free webinar, the featured speakers will shed light on the clinical and commercial reality of NGS in oncology, with predictions for what lies ahead in the United States and Europe.
Speakers will be Bruce Quinn, and Joseph Ferraro, President and CEO of Boston Healthcare Associates.